- Home
- KMI vs TNGX Comparison
KMI vs TNGX Comparison
Compare KMI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMI
- TNGX
- Stock Information
- Founded
- KMI 1936
- TNGX 2014
- Country
- KMI United States
- TNGX United States
- Employees
- KMI N/A
- TNGX N/A
- Industry
- KMI Natural Gas Distribution
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- KMI Utilities
- TNGX Health Care
- Exchange
- KMI Nasdaq
- TNGX Nasdaq
- Market Cap
- KMI 52.4B
- TNGX 735.0M
- IPO Year
- KMI 2011
- TNGX N/A
- Fundamental
- Price
- KMI $24.82
- TNGX $6.64
- Analyst Decision
- KMI Buy
- TNGX Strong Buy
- Analyst Count
- KMI 13
- TNGX 8
- Target Price
- KMI $24.92
- TNGX $15.14
- AVG Volume (30 Days)
- KMI 14.3M
- TNGX 885.7K
- Earning Date
- KMI 10-16-2024
- TNGX 11-06-2024
- Dividend Yield
- KMI 4.63%
- TNGX N/A
- EPS Growth
- KMI 3.81
- TNGX N/A
- EPS
- KMI 1.13
- TNGX N/A
- Revenue
- KMI $15,151,000,000.00
- TNGX $42,509,000.00
- Revenue This Year
- KMI $3.78
- TNGX $18.15
- Revenue Next Year
- KMI $4.96
- TNGX N/A
- P/E Ratio
- KMI $21.90
- TNGX N/A
- Revenue Growth
- KMI N/A
- TNGX 26.16
- 52 Week Low
- KMI $15.91
- TNGX $6.33
- 52 Week High
- KMI $25.43
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- KMI 74.01
- TNGX 37.15
- Support Level
- KMI $24.50
- TNGX $6.83
- Resistance Level
- KMI $25.01
- TNGX $7.47
- Average True Range (ATR)
- KMI 0.48
- TNGX 0.37
- MACD
- KMI 0.06
- TNGX 0.11
- Stochastic Oscillator
- KMI 76.89
- TNGX 27.31
About KMI Kinder Morgan Inc.
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 82,000 miles in pipelines and 139 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.